Blog

Oct 20, 2024

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics | Nature Reviews Drug Discovery

Nature Reviews Drug Discovery (2024)Cite this article Metrics details Remarkable progress has been made in recent decades in engineering antibodies and other protein therapeutics, including

Nature Reviews Drug Discovery (2024)Cite this article

Metrics details

Remarkable progress has been made in recent decades in engineering antibodies and other protein therapeutics, including enhancements to existing functions as well as the advent of novel molecules that confer biological activities previously unknown in nature. These protein therapeutics have brought major benefits to patients across multiple areas of medicine. One major ongoing challenge is that protein therapeutics can elicit unwanted immune responses (immunogenicity) in treated patients, including the generation of anti-drug antibodies. In rare and unpredictable cases, anti-drug antibodies can seriously compromise therapeutic safety and/or efficacy. Systematic deconvolution of this immunogenicity problem is confounded by the complexity of its many contributing factors and the inherent limitations of available experimental and computational methods. Nevertheless, continued progress with the assessment and mitigation of immunogenicity risk at the preclinical stage has the potential to reduce the incidence and severity of clinical immunogenicity events. This Review focuses on identifying key unsolved anti-drug antibody-related challenges and offers some pragmatic approaches towards addressing them. Examples are drawn mainly from antibodies, given that the majority of available clinical data are from this class of protein therapeutics. Plausible and seemingly tractable solutions are in sight for some immunogenicity problems, whereas other challenges will likely require completely new approaches.

This is a preview of subscription content, access via your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$29.99 / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Walsh, G. & Walsh, E. Biopharmaceutical benchmarks 2022. Nat. Biotechnol. 40, 1722–1760 (2022).

Article CAS PubMed PubMed Central Google Scholar

Fülöp, T., Mészáros, T., Kozma, G. T., Szebeni, J. & Józsi, M. Infusion reactions associated with the medical application of monoclonal antibodies: the role of complement activation and possibility of inhibition by factor H. Antibodies 7, 14 (2018).

Article PubMed PubMed Central Google Scholar

Rombouts, M. D., Swart, E. L., van den Eertwegh, A. J. M. & Crul, M. Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res. 40, 1201–1218 (2020).

Article CAS PubMed Google Scholar

Sala-Cunill, A., Luengo, O. & Cardona, V. Biologics and anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 19, 439–446 (2019).

Article CAS PubMed Google Scholar

Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).

Article PubMed PubMed Central Google Scholar

Krishna, M. & Nadler, S. G. Immunogenicity to biotherapeutics – the role of anti-drug immune complexes. Front. Immunol. 7, 21 (2016).

Article PubMed PubMed Central Google Scholar

Gunn, G. R. et al. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin. Exp. Immunol. 184, 137–146 (2016).

Article PubMed PubMed Central Google Scholar

Cassotta, A. et al. A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients. Nat. Med. 25, 1402–1407 (2019). This ABIRISK consortium study creates and characterizes panels of monoclonal antibodies from two anti-natalizumab antibody-positive patients.

Article CAS PubMed PubMed Central Google Scholar

Mehta, P. & Manson, J. J. What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis? Front. Immunol. 11, 589 (2020).

Article CAS PubMed PubMed Central Google Scholar

Ridker, P. M. et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Engl. J. Med. 376, 1517–1526 (2017). Multiple phase III clinical studies of a humanized antibody (bococizumab) in thousands of patients reveals high rates of ADAs that correlate with adverse effects on pharmacokinetics and efficacy.

Article CAS PubMed Google Scholar

Yu, R. J., Krantz, M. S., Phillips, E. J. & Stone, C. A. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J. Allergy Clin. Immunol. Pract. 9, 819–829.e2 (2021).

Article CAS PubMed Google Scholar

Chung, C. H. et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med. 358, 1109–1117 (2008).

Article CAS PubMed PubMed Central Google Scholar

Casadevall, N. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469–475 (2002). Ground-breaking report that demonstrates that ADAs to protein therapeutics can on rare occasions have a severe clinical impact.

Article CAS PubMed Google Scholar

Schellekens, H. & Jiskoot, W. Eprex-associated pure red cell aplasia and leachates. Nat. Biotechnol. 24, 613–614 (2006).

Article CAS PubMed Google Scholar

McKoy, J. M. et al. Epoetin‐associated pure red cell aplasia: past, present, and future considerations. Transfusion 48, 1754–1762 (2008).

Article PubMed PubMed Central Google Scholar

Rubic-Schneider, T. et al. T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia. Blood Adv. 1, 367–379 (2017).

Article CAS PubMed PubMed Central Google Scholar

Gibbons, J. B., Laber, M. & Bennett, C. L. Humira: the first $20 billion drug. Am. J. Manag. Care 29, 78–80 (2023).

Article PubMed Google Scholar

Highlights of prescribing information, HUMIRA® (adalimumab) injection, for subcutaneous use. US Food and Drug Administration www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf (2018).

Bartelds, G. M. et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305, 1460–1468 (2011).

Article CAS PubMed Google Scholar

Murdaca, G. et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin. Drug Saf. 15, 43–52 (2016).

Article CAS PubMed Google Scholar

Koren, E. et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333, 1–9 (2008).

Article CAS PubMed Google Scholar

Mire-Sluis, A. R. et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289, 1–16 (2004).

Article CAS PubMed Google Scholar

Shankar, G. et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 16, 658–673 (2014).

Article CAS PubMed PubMed Central Google Scholar

Immunogenicity assessment for therapeutic protein products. Docket number: FDA-2013-D-0092. US Food and Drug Administration www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-assessment-therapeutic-protein-products (2014).

Immunogenicity testing of therapeutic protein products — developing and validating assays for anti-drug antibody detection. Docket number FDA-2009-D-0539. US Food and Drug Administration www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug (2019).

Immunogenicity assessment of biotechnology-derived therapeutic proteins — scientific guideline EMEA/CHMP/BMWP/14327/2006 Rev 1. European Medicines Agency www.ema.europa.eu/en/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-scientific-guideline (2017).

Carter, P. J. & Rajpal, A. Designing antibodies as therapeutics. Cell 185, 2789–2805 (2022).

Article CAS PubMed Google Scholar

Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).

Article CAS PubMed PubMed Central Google Scholar

Abbas, A. K., Lichtman, A. H. & Pillai, S. in Cellular and Molecular Immunology 10th edn, Ch. 6 (Elsevier, 2021).

Cornaby, C. et al. B cell epitope spreading: mechanisms and contribution to autoimmune diseases. Immunol. Lett. 163, 56–68 (2015).

Article CAS PubMed Google Scholar

Fahlquist-Hagert, C. et al. Antigen presentation by B cells enables epitope spreading across an MHC barrier. Nat. Commun. 14, 6941 (2023).

Article CAS PubMed PubMed Central Google Scholar

Murphy, K. M., Weaver, C. & Berg, L. J. Janeway’s Immunobiology (eds Twitchell, B. & Barrett-Bressack, C.) 10th edn (W. W. Norton and Company, 2022).

Moore, W. V. & Leppert, P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51, 691–697 (1980). Early study demonstrating that the incidence of ADAs in patients treated with human growth hormone correlates with the level of aggregates.

Article CAS PubMed Google Scholar

Joubert, M. K. et al. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J. Biol. Chem. 287, 25266–25279 (2012).

Article CAS PubMed PubMed Central Google Scholar

Bessa, J. et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm. Res. 32, 2344–2359 (2015).

Article CAS PubMed Google Scholar

Kretsinger, J. et al. Expectations for phase-appropriate drug substance and drug product specifications for early-stage protein therapeutics. J. Pharm. Sci. 108, 1442–1452 (2019).

Article CAS PubMed Google Scholar

Casasola-LaMacchia, A. et al. HLAII peptide presentation of infliximab increases when complexed with TNF. Front. Immunol. 13, 932252 (2022).

Article CAS PubMed PubMed Central Google Scholar

Kroenke, M. A. et al. Immune complex formation is associated with loss of tolerance and an antibody response to both drug and target. Front. Immunol. 12, 782788 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wilkinson, I. et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE 16, e0260954 (2021).

Article CAS PubMed PubMed Central Google Scholar

Siegel, M. et al. Validation of a dendritic cell and CD4+ T cell restimulation assay contributing to the immunogenicity risk evaluation of biotherapeutics. Pharmaceutics 14, 2672 (2022).

Article CAS PubMed PubMed Central Google Scholar

Tatarewicz, S. M. et al. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis 6, 1509–1523 (2014).

Article CAS PubMed Google Scholar

Wadhwa, M. & Thorpe, R. Harmonization and standardization of immunogenicity assessment of biotherapeutic products. Bioanalysis 11, 1593–1604 (2019).

Article CAS PubMed Google Scholar

Gorovits, B. Antidrug antibody assay validation: industry survey results. AAPS J. 11, 133–138 (2009).

Article CAS PubMed PubMed Central Google Scholar

Starcevic Manning, M. et al. Comparison of titer and signal to noise (S/N) for determination of anti-drug antibody magnitude using clinical data from an industry consortium. AAPS J. 24, 81 (2022).

Article CAS PubMed Google Scholar

Pratt, K. P. Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity. Antibodies 7, 19 (2018).

Article CAS PubMed PubMed Central Google Scholar

Hofbauer, C. J. et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 125, 1180–1188 (2015).

Article CAS PubMed Google Scholar

Wu, B. et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. AAPS J. 18, 1335–1350 (2016).

Article CAS PubMed Google Scholar

Büttel, I. C. et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39, 100–109 (2011).

Article PubMed Google Scholar

Deal, C. L. et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J. Clin. Endocrinol. Metab. 107, e2717–e2728 (2022).

Article PubMed PubMed Central Google Scholar

Fineberg, S. E. et al. Immunological responses to exogenous insulin. Endocr. Rev. 28, 625–652 (2007).

Article CAS PubMed Google Scholar

Gorovits, B. Current considerations for immunoglobulin isotype characterization of antibody response against biotherapeutics. AAPS J. 22, 144 (2020).

Article CAS PubMed Google Scholar

Carrasco-Triguero, M. et al. Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5, 1007–1023 (2013).

Article CAS PubMed Google Scholar

Myler, H. et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 24, 4 (2021).

Article PubMed Google Scholar

Lundahl, M. L. E., Fogli, S., Colavita, P. E. & Scanlan, E. M. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem. Biol. 2, 1004–1020 (2021).

Article CAS PubMed PubMed Central Google Scholar

Jawa, V., Maamary, J., Swanson, M., Zhang, S. & Montgomery, D. Implementing a clinical immunogenicity strategy using preclinical risk assessment outputs. J. Pharm. Sci. 111, 960–969 (2022).

Article CAS PubMed Google Scholar

Ducret, A. et al. Assay format diversity in pre-clinical immunogenicity risk assessment: toward a possible harmonization of antigenicity assays. mAbs 14, 1993522 (2022).

Article PubMed Google Scholar

Ulitzka, M. et al. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem. Protein Eng. Des. Sel. 33, gzaa025 (2020).

Article PubMed Google Scholar

Nilsson, J. B. et al. Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning. Sci. Adv. 9, eadj6367 (2023). In silico tool (NetMHCIIpan-4.3) refined by machine learning for high-accuracy prediction of antigen presentation across all human leukocyte antigen class II allotypes.

Article CAS PubMed PubMed Central Google Scholar

Chen, B. et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat. Biotechnol. 37, 1332–1343 (2019).

Article CAS PubMed PubMed Central Google Scholar

Thrift, W. J. et al. Graph-pMHC: graph neural network approach to MHC class II peptide presentation and antibody immunogenicity. Brief. Bioinform. 25, bbae123 (2024).

Article PubMed PubMed Central Google Scholar

Prihoda, D. et al. BioPhi: a platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. mAbs 14, 2020203 (2022).

Article PubMed PubMed Central Google Scholar

Attermann, A. S. et al. Improved prediction of HLA antigen presentation hotspots: applications for immunogenicity risk assessment of therapeutic proteins. Immunology 162, 208–219 (2021).

Article CAS PubMed Google Scholar

Ramon, A. et al. Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV. Nat. Mach. Intell. 6, 74–91 (2024).

Article Google Scholar

Racle, J. et al. Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes. Immunity 56, 1359–1375.e13 (2023).

Article CAS PubMed Google Scholar

Melendez, R. et al. Introducing dendritic cell antibody internalization as an immunogenicity risk assessment tool. Bioanalysis 14, 703–713 (2022).

Article CAS PubMed Google Scholar

Wen, Y. et al. Development of a FRET-based assay for analysis of mAbs internalization and processing by dendritic cells in preclinical immunogenicity risk assessment. AAPS J. 22, 68 (2020).

Article CAS PubMed Google Scholar

Röhn, T. A. et al. A novel strategy for the discovery of MHC class II–restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res. 65, 10068–10078 (2005).

Article PubMed Google Scholar

Steiner, G. et al. Enabling routine MHC-II-associated peptide proteomics for risk assessment of drug-induced immunogenicity. J. Proteome Res. 19, 3792–3806 (2020).

Article CAS PubMed Google Scholar

Lee, M. V. et al. Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development. Front. Immunol. 14, 1295285 (2023).

Article CAS PubMed PubMed Central Google Scholar

Hartman, K. et al. Expanding the MAPPs assay to accommodate MHC-II pan receptors for improved predictability of potential T cell epitopes. Biology 12, 1265 (2023).

Article CAS PubMed PubMed Central Google Scholar

Jiang, W. & Boder, E. T. High-throughput engineering and analysis of peptide binding to class II MHC. Proc. Natl Acad. Sci. USA 107, 13258–13263 (2010).

Article CAS PubMed PubMed Central Google Scholar

Arata, Y. et al. Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion. mAbs 15, 2253570 (2023).

Article PubMed PubMed Central Google Scholar

Cohen, S. et al. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells. mAbs 13, 1898831 (2021).

Article PubMed PubMed Central Google Scholar

Walsh, R. E. et al. Post hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. mAbs 12, 1764829 (2020).

Article PubMed PubMed Central Google Scholar

Ito, S. et al. In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. J. Immunotoxicol. 16, 125–132 (2019).

Article CAS PubMed Google Scholar

Ponce, R. et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54, 164–182 (2009).

Article CAS PubMed Google Scholar

Swanson, S. J. & Bussiere, J. Immunogenicity assessment in non-clinical studies. Curr. Opin. Microbiol. 15, 337–347 (2012).

Article CAS PubMed Google Scholar

van Meer, P. J. et al. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. mAbs 5, 810–816 (2013).

Article PubMed PubMed Central Google Scholar

Egli, J. et al. Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice. mAbs 14, 2143009 (2022).

Article PubMed PubMed Central Google Scholar

Brennan, F. R. et al. Safety testing of monoclonal antibodies in non-human primates: case studies highlighting their impact on human risk assessment. mAbs 10, 1–17 (2017).

Article PubMed PubMed Central Google Scholar

Gokemeijer, J. et al. Survey outcome on immunogenicity risk assessment tools for biotherapeutics: an insight into consensus on methods, application, and utility in drug development. AAPS J. 25, 55 (2023).

Article PubMed Google Scholar

Quarmby, V., Phung, Q. T. & Lill, J. R. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. Expert Rev. Proteomics 15, 733–748 (2018).

Article CAS PubMed Google Scholar

Sekiguchi, N. et al. MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. mAbs 10, 1168–1181 (2018).

Article CAS PubMed PubMed Central Google Scholar

Egholm Bruun Jensen, E., Reynisson, B., Barra, C. & Nielsen, M. New light on the HLA-DR immunopeptidomic landscape. J. Leukoc. Biol. 115, 913–925 (2024).

Article PubMed Google Scholar

Tsai, W. K. et al. Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies. mAbs 16, 2362789 (2024). First direct evidence to support the validity of the widespread practice of using research-grade antibody preparations to investigate the immunogenicity risk of their pharmaceutical counterparts.

Article PubMed PubMed Central Google Scholar

Xue, L., Hickling, T., Song, R., Nowak, J. & Rup, B. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody. Clin. Exp. Immunol. 183, 102–113 (2016).

Article CAS PubMed Google Scholar

Zinsli, L. V., Stierlin, N., Loessner, M. J. & Schmelcher, M. Deimmunization of protein therapeutics — recent advances in experimental and computational epitope prediction and deletion. Comput. Struct. Biotechnol. J. 19, 315–329 (2021).

Article CAS PubMed Google Scholar

Kearns, J. D. et al. A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab. Sci. Transl. Med. 15, eabq5068 (2023).

Article CAS PubMed Google Scholar

Kuroda, D. & Tsumoto, K. Engineering stability, viscosity, and immunogenicity of antibodies by computational design. J. Pharm. Sci. 109, 1631–1651 (2020).

Article CAS PubMed Google Scholar

Sampei, Z. et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE 8, e57479 (2013).

Article CAS PubMed PubMed Central Google Scholar

Schmitt, C. et al. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia 27, 984–992 (2021). Together with Sampei et al. (2013), demonstrates that it is possible to extensively engineer a protein therapeutic (bispecific antibody) with low incidence of ADAs.

Article CAS PubMed PubMed Central Google Scholar

Mazor, R. et al. Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. Cell. Mol. Immunol. 14, 432–442 (2017). Demonstration of immunogenicity risk mitigation by engineering out T cell epitopes in a recombinant immunotoxin to prevent the formation of ADAs in immune-competent mice.

Article CAS PubMed Google Scholar

Mazor, R. & Pastan, I. Immunogenicity of immunotoxins containing Pseudomonas exotoxin A: causes, consequences, and mitigation. Front. Immunol. 11, 1261 (2020).

Article CAS PubMed PubMed Central Google Scholar

Therapeutic monoclonal antibodies approved or in regulatory review. The Antibody Society www.antibodysociety.org/antibody-therapeutics-product-data (accessed 3 May 2024).

Boulianne, G. L., Hozumi, N. & Shulman, M. J. Production of functional chimaeric mouse/human antibody. Nature 312, 643–646 (1984).

Article CAS PubMed Google Scholar

Morrison, S. L., Johnson, M. J., Herzenberg, L. A. & Oi, V. T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl Acad. Sci. USA 81, 6851–6855 (1984).

Article CAS PubMed PubMed Central Google Scholar

Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).

Article CAS PubMed Google Scholar

Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323–327 (1988).

Article CAS PubMed Google Scholar

Verhoeyen, M., Milstein, C. & Winter, G. Reshaping human antibodies: grafting an antilysozyme activity. Science 239, 1534–1536 (1988).

Article CAS PubMed Google Scholar

Foote, J. & Winter, G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224, 487–499 (1992).

Article CAS PubMed Google Scholar

Vaughan, T. J. et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14, 309–314 (1996).

Article CAS PubMed Google Scholar

Fishwild, D. M. et al. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14, 845–851 (1996).

Article CAS PubMed Google Scholar

Mendez, M. J. et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146–156 (1997).

Article CAS PubMed Google Scholar

Lee, E. C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356–363 (2014).

Article CAS PubMed Google Scholar

Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl Acad. Sci. USA 111, 5153–5158 (2014).

Article CAS PubMed PubMed Central Google Scholar

Baek, D. S. & Kim, Y. S. Construction of a large synthetic human Fab antibody library on yeast cell surface by optimized yeast mating. J. Microbiol. Biotechnol. 24, 408–420 (2014).

Article CAS PubMed Google Scholar

Kelly, R. L., Le, D., Zhao, J. & Wittrup, K. D. Reduction of nonspecificity motifs in synthetic antibody libraries. J. Mol. Biol. 430, 119–130 (2018).

Article CAS PubMed Google Scholar

Gieselmann, L. et al. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nat. Protoc. 16, 3639–3671 (2021).

Article CAS PubMed Google Scholar

Marks, C., Hummer, A. M., Chin, M. & Deane, C. M. Humanization of antibodies using a machine learning approach on large-scale repertoire data. Bioinformatics 37, 4041–4047 (2021). Demonstration of a negative correlation between humanness score and clinical ADA incidence for antibodies.

Article CAS PubMed PubMed Central Google Scholar

Jain, T., Boland, T. & Vasquez, M. Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches. mAbs 15, 2200540 (2023).

Article PubMed PubMed Central Google Scholar

Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944–949 (2017). Pioneering developability assessment of a large panel (n = 137) of clinical-stage antibodies to empirically define the boundaries of drug-like behaviour.

Article CAS PubMed PubMed Central Google Scholar

Hua, F. et al. Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J. Clin. Pharmacol. 54, 14–22 (2014).

Article CAS PubMed Google Scholar

Lowe, S. L. et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement. 7, e12112 (2021).

Google Scholar

Baker, M., Reynolds, H. M., Lumicisi, B. & Bryson, C. J. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 1, 314–322 (2010).

Article PubMed PubMed Central Google Scholar

Harris, C. T. & Cohen, S. Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs 38, 205–226 (2024).

Article CAS PubMed PubMed Central Google Scholar

Myler, H. et al. Report on the AAPS immunogenicity guidance forum. AAPS J. 21, 55 (2019).

Article PubMed Google Scholar

Wyant, T., Yang, L. & Rosario, M. Comparison of the ELISA and ECL assay for vedolizumab anti-drug antibodies: assessing the impact on pharmacokinetics and safety outcomes of the phase 3 GEMINI trials. AAPS J. 23, 3 (2020).

Article PubMed Google Scholar

Davda, J. et al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J. Immunother. Cancer 7, 105 (2019).

Article PubMed PubMed Central Google Scholar

Enrico, D., Paci, A., Chaput, N., Karamouza, E. & Besse, B. Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin. Cancer Res. 26, 787–792 (2020).

Article CAS PubMed Google Scholar

Clavero-Alvarez, A., Di Mambro, T., Perez-Gaviro, S., Magnani, M. & Bruscolini, P. Humanization of antibodies using a statistical inference approach. Sci. Rep. 8, 14820 (2018).

Article PubMed PubMed Central Google Scholar

Tourdot, S. & Hickling, T. P. Nonclinical immunogenicity risk assessment of therapeutic proteins. Bioanalysis 11, 1631–1643 (2019).

Article CAS PubMed Google Scholar

Dyson, M. R. et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. mAbs 12, 1829335 (2020). Demonstration that improving the biophysical properties of an antibody (bococizumab) correlates with a reduced immunogenicity risk in nonclinical assays.

Article PubMed PubMed Central Google Scholar

Wen, Y. & Jawa, V. The impact of product and process related critical quality attributes on immunogenicity and adverse immunological effects of biotherapeutics. J. Pharm. Sci. 110, 1025–1041 (2021).

Article CAS PubMed Google Scholar

Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J. & Narhi, L. O. Classification and characterization of therapeutic antibody aggregates. J. Biol. Chem. 286, 25118–25133 (2011).

Article CAS PubMed PubMed Central Google Scholar

Dang, X. et al. Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies. mAbs 15, 2285285 (2023).

Article PubMed PubMed Central Google Scholar

Geraldes, D. C. et al. Protein drug delivery: current dosage form profile and formulation strategies. J. Drug Target. 28, 339–355 (2019).

Article PubMed Google Scholar

Ghosh, I., Gutka, H., Krause, M. E., Clemens, R. & Kashi, R. S. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations. mAbs 15, 2205540 (2023).

Article PubMed PubMed Central Google Scholar

Strickley, R. G. & Lambert, W. J. A review of formulations of commercially available antibodies. J. Pharm. Sci. 110, 2590–2608.e56 (2021).

Article CAS PubMed Google Scholar

Davis, J. D. et al. Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development. Clin. Pharmacol. Ther. 115, 422–439 (2024).

Article CAS PubMed Google Scholar

Felderman, J., Ramaiah, L., Vazquez-Abad, M. D., Messing, D. & Chen, Y. Anti-drug antibody incidence comparison of therapeutic proteins administered via subcutaneous vs. intravenous route. AAPS J. 26, 60 (2024).

Article CAS PubMed Google Scholar

Hamuro, L. et al. Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J. Pharm. Sci. 106, 2946–2954 (2017).

Article CAS PubMed Google Scholar

Jarvi, N. L. & Balu-Iyer, S. V. Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins. BioDrugs 35, 125–146 (2021).

Article PubMed PubMed Central Google Scholar

Holland, M. C. et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J. Clin. Immunol. 33, 1192–1203 (2013).

Article CAS PubMed Google Scholar

Cordy, J. C. et al. Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1. Clin. Exp. Immunol. 182, 139–148 (2015). B cell epitope mapping is used to redesign VH domain antibodies with minimal reactivity to pre-existing autoantibodies.

Article CAS PubMed PubMed Central Google Scholar

Brezski, R. J. et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J. Immunol. 181, 3183–3192 (2008).

Article CAS PubMed Google Scholar

Mellbye, O. J. & Natvig, J. B. Evidence for immune complexes containing antibody to the pepsin site of IgG in rheumatoid synovial fluids. Clin. Exp. Immunol. 8, 889–899 (1971).

CAS PubMed PubMed Central Google Scholar

Rispens, T. et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J. Immunol. Methods 375, 93–99 (2012).

Article CAS PubMed Google Scholar

Terness, P. et al. The natural human IgG anti-F(ab’)2 antibody recognizes a conformational IgG1 hinge epitope. J. Immunol. 154, 6446–6452 (1995).

Article CAS PubMed Google Scholar

Kim, H. S. et al. Evading pre-existing anti-hinge antibody binding by hinge engineering. mAbs 8, 1536–1547 (2016). B cell epitope mapping that facilitates the design of Fab and F(ab’)2 fragments with minimal reactivity to pre-existing anti-hinge autoantibodies.

Article CAS PubMed PubMed Central Google Scholar

Barker, D. J. et al. The IPD-IMGT/HLA database. Nucleic Acids Res. 51, D1053–D1060 (2023).

Article CAS PubMed Google Scholar

McKinney, D. M. et al. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics 65, 357–370 (2013).

Article CAS PubMed PubMed Central Google Scholar

McGill, J. R., Yogurtcu, O. N., Verthelyi, D., Yang, H. & Sauna, Z. E. SampPick: selection of a cohort of subjects matching a population HLA distribution. Front. Immunol. 10, 2894 (2019).

Article CAS PubMed PubMed Central Google Scholar

Yogurtcu, O. N., Sauna, Z. E., McGill, J. R., Tegenge, M. A. & Yang, H. TCPro: an in silico risk assessment tool for biotherapeutic protein immunogenicity. AAPS J. 21, 96 (2019).

Article PubMed Google Scholar

Mahlangu, J. N. et al. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J. Thromb. Haemost. 13, 1989–1998 (2015).

Article CAS PubMed Google Scholar

Lamberth, K. et al. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Sci. Transl. Med. 9, eaag1286 (2017). A post hoc assessment showing that a new T cell epitope is inadvertently created when three amino acid substitutions are made in factor VIIa to create vatreptacog alfa.

Article PubMed Google Scholar

Jaber, A. & Baker, M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J. Pharm. Biomed. Anal. 43, 1256–1261 (2007).

Article CAS PubMed Google Scholar

Jaber, A. et al. The Rebif new formulation story: it’s not trials and error. Drugs R D 8, 335–348 (2007).

Article CAS PubMed Google Scholar

Giovannoni, G. et al. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult. Scler. J. 15, 219–228 (2009).

Article CAS Google Scholar

Alt, N. et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals 44, 291–305 (2016).

Article CAS PubMed Google Scholar

Jawa, V. et al. Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics. AAPS J. 18, 1439–1452 (2016).

Article CAS PubMed Google Scholar

Barra, C. et al. Immunopeptidomic data integration to artificial neural networks enhances protein-drug immunogenicity prediction. Front. Immunol. 11, 1304 (2020).

Article CAS PubMed PubMed Central Google Scholar

Duhazé, J. et al. A machine learning approach for high-dimensional time-to-event prediction with application to immunogenicity of biotherapies in the ABIRISK cohort. Front. Immunol. 11, 608 (2020).

Article PubMed PubMed Central Google Scholar

Sun, R., Qian, M. G. & Zhang, X. T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics. mAbs 16, 2324836 (2024).

Article PubMed PubMed Central Google Scholar

Vanderlaan, M. et al. Changes in manufacturing processes of biologic therapies can alter the immunogenicity profile of the product. Clin. Pharmacol. Ther. 107, 988–993 (2020).

Article CAS PubMed Google Scholar

Vagenende, V., Yap, M. G. & Trout, B. L. Mechanisms of protein stabilization and prevention of protein aggregation by glycerol. Biochemistry 48, 11084–11096 (2009).

Article CAS PubMed Google Scholar

Fleischman, M. L., Chung, J., Paul, E. P. & Lewus, R. A. Shipping-induced aggregation in therapeutic antibodies: utilization of a scale-down model to assess degradation in monoclonal antibodies. J. Pharm. Sci. 106, 994–1000 (2017).

Article CAS PubMed Google Scholar

Fischer, S. K. et al. Specific immune response to phospholipase B-like 2 protein, a host cell impurity in lebrikizumab clinical material. AAPS J. 19, 254–263 (2017).

Article CAS PubMed Google Scholar

Molden, R. et al. Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development. mAbs 13, 1955811 (2021).

Article PubMed PubMed Central Google Scholar

Jones, M. et al. “High-risk” host cell proteins (HCPs): a multi-company collaborative view. Biotechnol. Bioeng. 118, 2870–2885 (2021).

Article CAS PubMed Google Scholar

Gupta, S., Jiskoot, W., Schöneich, C. & Rathore, A. S. Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and efficacy. J. Pharm. Sci. 111, 903–918 (2022).

Article CAS PubMed Google Scholar

Chen, B. M., Cheng, T. L. & Roffler, S. R. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano 15, 14022–14048 (2021).

Article CAS PubMed Google Scholar

Highlights of prescribing information, Rituxan (rituximab) injection for intravenous use. US Food and Drug Administration www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf (2010).

Papadopoulos, K. P. et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother. Pharmacol. 75, 887–895 (2015).

Article CAS PubMed Google Scholar

Ducourau, E. et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open 6, e001047 (2020).

Article PubMed PubMed Central Google Scholar

Peters, S. et al. Obinutuzumab pretreatment as a novel approach to mitigate formation of anti-drug antibodies against cergutuzumab amunaleukin in patients with solid tumors. Clin. Cancer Res. 30, 1630–1641 (2024).

Article CAS PubMed Google Scholar

Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449–W454 (2020).

Article CAS PubMed PubMed Central Google Scholar

Desai, A. K., Kazi, Z. B., Bali, D. S. & Kishnani, P. S. Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol. Genet. Metab. Rep. 20, 100475 (2019).

Article PubMed PubMed Central Google Scholar

Messinger, Y. H. et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 14, 135–142 (2012).

Article CAS PubMed PubMed Central Google Scholar

Sands, E. et al. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nat. Commun. 13, 272 (2022).

Article CAS PubMed PubMed Central Google Scholar

Cia, G., Pucci, F. & Rooman, M. Critical review of conformational B-cell epitope prediction methods. Brief. Bioinform. 24, bbac567 (2023).

Article PubMed Google Scholar

Lin, J. et al. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PLoS ONE 16, e0254944 (2021).

Article CAS PubMed PubMed Central Google Scholar

Download references

We thank the following Genentech colleagues for their critical feedback of this article: M. Balazs, S. Cohen, J. Koerber, J. Lill, K. Peng, O. Saad, C. Spiess, S. Swanson, W.-T. Tsai and P. Wu.

Department of Antibody Engineering, Genentech, Inc., South San Francisco, CA, USA

Paul J. Carter

Department of BioAnalytical Sciences, Genentech, Inc., South San Francisco, CA, USA

Valerie Quarmby

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

P.J.C. and V.Q. researched data for this article and wrote it.

Correspondence to Paul J. Carter or Valerie Quarmby.

The authors are current (P.J.C.) or former (V.Q.) employees of Genentech, Inc., which develops and commercializes therapeutics, including antibodies and other proteins.

Nature Reviews Drug Discovery thanks John Desjarlais, George Georgiou and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

IPD-IMGT/HLA database: https://www.ebi.ac.uk/ipd/imgt/hla/about/statistics/

Any molecule that can bind specifically to an antibody and/or generate peptide fragments that bind to a major histocompatibility complex molecule and are specifically recognized by a T cell receptor.

Linear or conformational parts of an antigen that bind to an antibody.

(CQA). A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.

Modification of protein sequence to remove B cell and/or T cell epitopes.

Broad set of desirable drug-like properties of protein therapeutics that includes feasibility of manufacture, stability during storage, ease of administration and favourable pharmacological behaviour in patients, and excludes target binding.

Diversification of the B and T cell epitopes recognized by the immune system.

Ability of an antibody to bind multiple self and/or foreign antigens that are unrelated to the cognate antigen(s).

Truncated and other modified forms, aggregates, precursors, and degradation products arising during manufacturing and/or storage.

Protein therapeutic that is intended to substitute or augment the deficiency of a specific endogenous protein.

Set of desired biochemical, biological and biophysical attributes for therapeutic candidates.

Peptides that are derived from an antigen that binds to a major histocompatibility complex molecule and are then recognized by cognate T cell receptors.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

Carter, P.J., Quarmby, V. Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nat Rev Drug Discov (2024). https://doi.org/10.1038/s41573-024-01051-x

Download citation

Accepted: 10 September 2024

Published: 18 October 2024

DOI: https://doi.org/10.1038/s41573-024-01051-x

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative